VectivBio Holding AG VECT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CH • USD

SharesGrow Score

43/100

2/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

VectivBio Holding AG (VECT) generated $54.1M in operating cash flow for quarter ending 2022-12-31. After capital expenditures of $42.75K, free cash flow was $54.15M.

Free cash flow margin was 8009.9% of revenue. Cash conversion ratio was -1.9x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was -1.9x suggests some earnings are non-cash items

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

43/100

SG Score

View full scorecard →

✓

VALUE

60/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

88/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

58/100

Proven by this page

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

VectivBio Holding AG Cash Flow History

Metric	TTM	Q4 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021
Operating Cash Flow	$0.00	$54.1M	$-18.03M	$-18.03M	$-18.03M
Capital Expenditure	$0.00	$42.75K	$-14.25K	$-14.25K	$-14.25K
Free Cash Flow	$0.00	$54.15M	$-18.05M	$-18.05M	$-18.05M